Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioma: early-phase trial registry
48 of 88 indexed Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #156 of 28,707 conditions by registered trial count.
88 US clinical trials · 48 currently recruiting · #156 of 28,707 conditions by registered trial count
Glioma: 88 US clinical trials tracked, 48 recruiting.
Glioma is the subject of 88 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 53 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition glioma
OPEN 48 | RECR 55% | LATE 3 | EARLY 53 | RANK #156 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Glioma lists 48 open slots (55% of 88 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioma is recruiting above its size-band peers.
48 of 88 indexed trials (54.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 8 of 88 trials (9.1%). 51 distinct sponsors appear on at least one study for this condition label.
-
Most Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 88 trials that report a genuine target (sentinel values excluded). 67 of those (76.1%) plan for fewer than 100 participants.
-
Glioma research is mostly interventional.
78 interventional and 10 observational studies make up this index (88.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
88 total, page 1 of 2
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
M.D. Anderson Cancer Center
NCT01772771
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Jazz Pharmaceuticals
NCT05580562
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nuvation Bio
NCT05303519
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
NCT05355701
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
Jona Hattangadi-Gluth
NCT05576103
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics
NCT06326411
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics
NCT07326566
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Cancer Institute (NCI)
NCT06161519
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Susan Chang
NCT03739411
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00870129
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
Mayo Clinic
NCT07074756
ASCENT Intervention for Brain Tumor Patients
Massachusetts General Hospital
NCT06099743
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
Mayo Clinic
NCT04047264
Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation
University of Colorado, Denver
NCT07050836
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
Washington University School of Medicine
NCT04975139
MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
M.D. Anderson Cancer Center
NCT04373720
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
St. Jude Children's Research Hospital
NCT04065776
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Case Comprehensive Cancer Center
NCT06101069
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Memorial Sloan Kettering Cancer Center
NCT05188508
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Stephen Bagley, MD, MSCE
NCT05345002
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
NCT01906385
Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
University of Rochester
NCT04543201
Glioma Developmental and HyperActive Ras Tumor (DHART) Board
Memorial Sloan Kettering Cancer Center
NCT05489783
NeuroPathways Intervention for Brain Tumor Patients
Massachusetts General Hospital
NCT05976490
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Plus Therapeutics
NCT05460507
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
NCT02800486
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
University of Maryland, Baltimore
NCT04699773
LITT Followed by Hypofractionated RT for Recurrent Gliomas
University of Maryland, Baltimore
NCT04181684
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Children's Hospital of Philadelphia
NCT05555550
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics
NCT06011109
Non-invasive Glioma Characterization Through Molecular Imaging
University of Miami
NCT03684109
18F-Fluciclovine PET-MRI in High-grade Glioma
Children's Hospital of Philadelphia
NCT05553041
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT06344130
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Baptist Health South Florida
NCT06397560
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
NCT06650163
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
NCT07223034
Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
OHSU Knight Cancer Institute
NCT05937776
Registering Genomics and Imaging of Tumors (ReGIT)
Indiana University
NCT05386043
A Study Utilizing Escitalopram in Glioma Patients
University of Nebraska
NCT03728673
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
NCT05607407
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT05686798
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
NCT07486713
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Nader Sanai
NCT05773326
Tumor Treating Fields for the Treatment of Brainstem Gliomas
Emory University
NCT05310448
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
Mayo Clinic
NCT07025226
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
University of Maryland, Baltimore
NCT04772456
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
Telix Pharmaceuticals (Innovations) Pty Limited
NCT07238322
Couples-Based Yoga Program in Improving Quality of Life in Patients With High-Grade Glioma Undergoing Radiation Therapy and Their Partners
M.D. Anderson Cancer Center
NCT02481349
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 38 |
| Phase 2 | 15 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioma page
88 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Glioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioma condition card totals 88 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.